--- title: LockSeq Service | Off-Target Confirmation, DNA-In to Report-Out | Countagen description: Send us your DNA and off-target coordinates. We return a UMI-corrected variant allele frequency report in 15 business days. No capital expenditure. No infrastructure. End-to-end service. --- [![Logo_horizontal_colored logo with black text](https://www.countagen.com/hubfs/Logo_horizontal_colored%20logo%20with%20black%20text.png)](https://www.countagen.com/?hsLang=en) - [Home](https://www.countagen.com) - [Technology](https://www.countagen.com/technology?hsLang=en) - [Resources](https://www.countagen.com/resources?hsLang=en) - [FAQ](https://www.countagen.com/faq?hsLang=en) - [About Us](https://www.countagen.com/about-us?hsLang=en) [REQUEST A QUOTE](https://www.countagen.com/about-us?hsLang=en#get-in-touch-form) # Your Off-Target Confirmation Partner — From Coordinates to Report You define the targets. We handle the rest. LockSeq runs as a complete service — probe design, library prep, sequencing, analysis, and reporting — delivered in 15 business days. No instrument investment. No bioinformatics overhead. THE REGULATORY CONTEXT ## FDA Now Requires Orthogonal Off-Target Assessment The FDA's April 2026 Draft Guidance on genome editing safety explicitly calls for orthogonal confirmation methods — independent of the nomination assay — for IND-enabling submissions. As panel size grows, maintaining sensitivity and complete target coverage becomes increasingly challenging. Missing sites are not just data gaps—they are genomic blind spots that can translate into development delays and regulatory risk.  LockSeq is purpose-built for this requirement. ![FDA Guidance](https://www.countagen.com/hubfs/FDA%20Guidance.png "FDA Guidance") LOCKSEQ SERVICE ## What's Included in Every LockSeq Study Countagen provides LockSeq as an end-to-end service model designed to eliminate the operational and infrastructure barriers of high-plex gene-editing validation. Focus on your therapeutic discovery while we deliver high-confidence edit detection. ![High-Level Workflow](https://www.countagen.com/hs-fs/hubfs/High-Level%20Workflow%20(3).png?width=2000&height=448&name=High-Level%20Workflow%20(3).png "High-Level Workflow") #1 — PROJECT SCOPING #### We review your edit design, gRNA sequences, and nominated off-target coordinates. Where needed, we can supplement with in silico nomination. Turnaround: Usually within 24 hours from first contact to project specification. #2 — PANEL CUSTOMIZATION #### We design padlock probes for all your on- and off-target loci — up to 1,000+ sites per reaction. Probes are validated *in silico* before synthesis. #### Mix-and-match of new targets across development stages without panel redesign. #3 — TECHNICAL EXECUTION #### LockSeq library preparation and sequencing are performed in our Stockholm laboratory. Illumina and Oxford Nanopore platforms confirmed. #4 — CONSENSUS REPORTING #### You receive a UMI-corrected variant allele frequency report with indel profiling, coverage uniformity charts, and raw data (FASTQ + BAM). Standard turnaround: 15 business days from DNA receipt. PRICING ## Transparent Starting Points LockSeq service pricing scales with panel size and sample number. Request a quote for your specific panel configuration. Most projects are scoped within 24 hours. [Request A Quote](https://www.countagen.com/about-us?hsLang=en#get-in-touch-form) PLATFORM ADVANTAGES ## Why Choose LockSeq  #### High-Confidence Edit Detection LockSeq uses gap-fill ligation to capture target molecules prior to amplification. UMI-based consensus sequencing suppresses technical errors, enabling confident detection of edits down to 0.1% VAF across panels exceeding 1,000 targets. #### Fewer Dropouts. Better Coverage. LockSeq is designed to minimize target dropout in highly multiplexed workflows. By reducing assay complexity and potential molecular interactions, the platform improves target representation and supports more complete genomic characterization across large panels. #### One Workflow. Any Scale. Reconfigure targets without assay redesign. LockSeq supports everything from single-site confirmation to >1,000-plex off-target characterization in a single workflow, with demonstrated compatibility across Illumina and ONT. TRUSTED BY ![Danish Cancer Institute](https://www.countagen.com/hs-fs/hubfs/Danish%20Cancer%20Institute.png?width=634&height=346&name=Danish%20Cancer%20Institute.png) ![Karolinska CRISPR Functional Genomics Unit](https://www.countagen.com/hs-fs/hubfs/Karolinska%20CRISPR%20Functional%20Genomics%20Unit.png?width=944&height=472&name=Karolinska%20CRISPR%20Functional%20Genomics%20Unit.png) ![University Freiburg](https://www.countagen.com/hs-fs/hubfs/University%20Freiburg.png?width=766&height=102&name=University%20Freiburg.png) ![NIST Gene Editing Consortium](https://www.countagen.com/hs-fs/hubfs/NIST%20Gene%20Editing%20Consortium.png?width=950&height=226&name=NIST%20Gene%20Editing%20Consortium.png) [![Countagen_Logo_White](https://www.countagen.com/hubfs/Logo_horizontal_colored%20logo%20with%20white%20text.png)](https://www.countagen.com) | Countagen AB Nobels väg 16 171 65 Solna Sweden | Registered supplier on [Scientist.com](https://app.scientist.com/providers/countagen-ab) [![Scientist.com](https://www.countagen.com/hs-fs/hubfs/Scientist-com.png?width=1244&height=259&name=Scientist-com.png)](https://app.scientist.com/providers/countagen-ab) | | --- | --- | ### Product - [LockSeq Service](https://www.countagen.com) - [FAQ](https://www.countagen.com/faq?hsLang=en) ### Technology - [Technology](https://www.countagen.com/technology?hsLang=en) - [Resources](https://www.countagen.com/resources?hsLang=en) ### Company - [About Us](https://www.countagen.com/about-us?hsLang=en) © 2026 Countagen AB All rights reserved [Terms of Use](https://www.countagen.com/terms-of-use?hsLang=en) [Privacy Policy](https://www.countagen.com/privacy-policy?hsLang=en) [Cookie Policy](https://www.countagen.com/cookie-policy?hsLang=en) [Powered by Atlas - a B2B SaaS HubSpot theme](https://www.kalungi.com/atlas-hubspot-theme-for-b2b-saas-software)